Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | Director · PRESIDENT AND CEO | May 14, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 833,949 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Gift · Disposed 400,000 · Balance 833,949 F1: The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 21:06 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GiftCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002007795-26-000006 · wk-form4_1778879168.xml · nonDerivative · entry 1 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,949 F1 · kind: The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 00:16 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Tax withholdingCommon Stock | 6,227 | $19.69 | $122,609.63 |
DisclosureSEC source: 0002007795-26-000002 · wk-form4_1772583360.xml · nonDerivative · entry 1 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,233,949 F1 · shares: Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 306,000 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0002007795-26-000001 · wk-form4_1771021213.xml · derivative · entry 1 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,000 Underlying: Common Stock · 306,000 shares Expires 2036-02-10 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 215,000 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 8 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 215,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F6 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 215,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 7 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F6 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 223,000 | Not disclosed Strike: $14.88 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 6 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 223,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 223,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 5 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,000 Underlying: Common Stock · 223,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 247,290 | Not disclosed Strike: $5.30 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 4 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 247,290 shares Expires 2033-12-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 247,290 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 3 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,290 Underlying: Common Stock · 247,290 shares Expires 2033-12-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 34,620 | Not disclosed Strike: $6.23 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 2 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,620 shares Expires 2033-04-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,620 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000063 · wk-form4_1752009676.xml · derivative · entry 1 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,620 Underlying: Common Stock · 34,620 shares Expires 2033-04-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001999480-25-000013 · wk-form4_1738963279.xml · derivative · entry 1 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:00 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 223,000 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001415889-24-006822 · form4-03052024_060301.xml · derivative · entry 2 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,000 Underlying: Common Stock · 223,000 shares Expires 2034-02-28 F3 · derivative.exercise_date: 25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:00 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantCommon Stock | 34,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006822 · form4-03052024_060301.xml · nonDerivative · entry 1 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,240,176 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in two equal installments on September 1, 2025 and March 1, 2026, subject to the Reporting Person's continuous service through each such vesting date. F2 · price: Each RSU represents a contingent right to receive one share of common stock. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:36 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries B Preferred Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002934 · form4-02072024_090241.xml · derivative · entry 3 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:36 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 3,125 | $16.00 | $50,000.00 |
DisclosureSEC source: 0001415889-24-002934 · form4-02072024_090241.xml · nonDerivative · entry 2 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,205,465 Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:36 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 11,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002934 · form4-02072024_090241.xml · nonDerivative · entry 1 Etkin Amit · CIK 0002007795 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,202,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.